Metastatic Breast Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Metastatic Breast Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting
-
Narrated by:
-
By:
About this listen
Featuring perspectives from Dr Harold J Burstein, Dr Javier Cortés, Prof Rebecca A Dent, Dr Kevin Kalinsky, Dr Hope S Rugo and Dr Joyce O’Shaughnessy, moderated by Dr Rugo, including the following topics:
- Introduction (0:00)
- Optimizing the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Dr Cortés (3:52)
- Individualized Selection of Up-Front Therapy for Patients with HR-Positive, HER2-Negative mBC — Dr Kalinsky (23:10)
- Available Therapies for Patients with HR-Positive, HER2-Negative Disease Progressing on CDK4/6 Inhibition — Dr Burstein (48:09)
- Current and Potential Future Role of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease — Dr O’Shaughnessy (1:04:00)
- Current and Future Strategies for Patients with Endocrine-Refractory HR-Positive mBC — Dr Rugo (1:22:28)
- Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Prof Dent (1:42:51)
CME information and select publications
No reviews yet